Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching toxicity-causing antiretroviral to enfuvirtide in HIV-infected patients
2004-001224-21Phase 4Completed
- Sponsor
- Roche
- Start
- Nov 2004
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enfuvirtide in human immunodeficiency virus infection (HIV), sponsored by Roche. Primary endpoints: Resolution or change in severity of offending antiretroviral toxicity and Safety and tolerability of enfuvirtide-based regimen. Started Nov 2004; status: completed.
02
Drugs
enfuvirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2004-001224-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001224-21.